GlassScriptPhysician profile
Daniel S Weeden
NPI 1144288317
$793.02
in general payments reported to CMS, 2019-2025
24 companies · $21.45 in 2025
The $21.45 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $188 · 2021: $166 · 2022: $141 · 2023: $126 · 2024: $29.88 · 2025: $21.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $177.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $137.55 | 2020-2022 | |
| Sanofi Pasteur INC. | $58.78 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $53.31 | 2020-2023 | Farxiga |
| Boston Scientific Corporation | $51.33 | 2024-2025 | Wavewriter Alpha Prime 16 |
| Merck Sharp & Dohme LLC | $46.66 | 2021 | |
| Novo Nordisk INC | $46.43 | 2020-2023 | Ozempic, Rybelsus |
| Genentech USA, INC. | $42.16 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $40.49 | 2022-2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $30.72 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.46 | 2021 | |
| Allergan, INC. | $27.95 | 2020 | |
| Abbvie INC. | $27.08 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $24.49 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.56 | 2022 | |
| Gilead Sciences, INC. | $19.24 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valeritas, INC. | $18.49 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.75 | 2023 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $17.50 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.77 | 2023 | Xifaxan, Trulance |
| Mylan Pharmaceuticals INC. | $16.14 | 2021 | |
| Glaxosmithkline, LLC. | $14.15 | 2019 | |
| Zealand Pharma US, INC. | $12.84 | 2020 | |
| Pfizer INC. | $11.20 | 2019 | |
| Ironshore Pharmaceuticals INC. | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Weeden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.